Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jared R. Mayers is active.

Publication


Featured researches published by Jared R. Mayers.


Cell | 2008

Identification of a Lipokine, a Lipid Hormone Linking Adipose Tissue to Systemic Metabolism

Haiming Cao; Kristin Gerhold; Jared R. Mayers; Michelle M. Wiest; Steven M. Watkins; Gökhan S. Hotamisligil

Dysregulation of lipid metabolism in individual tissues leads to systemic disruption of insulin action and glucose metabolism. Utilizing quantitative lipidomic analyses and mice deficient in adipose tissue lipid chaperones aP2 and mal1, we explored how metabolic alterations in adipose tissue are linked to whole-body metabolism through lipid signals. A robust increase in de novo lipogenesis rendered the adipose tissue of these mice resistant to the deleterious effects of dietary lipid exposure. Systemic lipid profiling also led to identification of C16:1n7-palmitoleate as an adipose tissue-derived lipid hormone that strongly stimulates muscle insulin action and suppresses hepatosteatosis. Our data reveal a lipid-mediated endocrine network and demonstrate that adipose tissue uses lipokines such as C16:1n7-palmitoleate to communicate with distant organs and regulate systemic metabolic homeostasis.


Nature Medicine | 2009

Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis.

Ebru Erbay; Vladimir R. Babaev; Jared R. Mayers; Liza Makowski; Khanichi N. Charles; Melinda Snitow; Sergio Fazio; Michelle M. Wiest; Steven M. Watkins; MacRae F. Linton; Gökhan S. Hotamisligil

Macrophages show endoplasmic reticulum (ER) stress when exposed to lipotoxic signals associated with atherosclerosis, although the pathophysiological importance and the underlying mechanisms of this phenomenon remain unknown. Here we show that mitigation of ER stress with a chemical chaperone results in marked protection against lipotoxic death in macrophages and prevents macrophage fatty acid–binding protein-4 (aP2) expression. Using genetic and chemical models, we show that aP2 is the predominant regulator of lipid-induced macrophage ER stress. The absence of lipid chaperones incites an increase in the production of phospholipids rich in monounsaturated fatty acids and bioactive lipids that render macrophages resistant to lipid-induced ER stress. Furthermore, the impact of aP2 on macrophage lipid metabolism and the ER stress response is mediated by upregulation of key lipogenic enzymes by the liver X receptor. Our results demonstrate the central role for lipid chaperones in regulating ER homeostasis in macrophages in atherosclerosis and show that ER responses can be modified, genetically or chemically, to protect the organism against the deleterious effects of hyperlipidemia.


Nature Medicine | 2014

Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development.

Jared R. Mayers; Chen Wu; Clary B. Clish; Peter Kraft; Margaret E. Torrence; Brian Prescott Fiske; Chen Yuan; Ying Bao; Mary K. Townsend; Shelley S. Tworoger; Shawn M. Davidson; Thales Papagiannakopoulos; Annan Yang; Talya L. Dayton; Shuji Ogino; Meir J. Stampfer; Edward Giovannucci; Zhi Rong Qian; Douglas A. Rubinson; Jing Ma; Howard D. Sesso; John Michael Gaziano; Barbara B. Cochrane; Simin Liu; Jean Wactawski-Wende; JoAnn E. Manson; Michael Pollak; Alec C. Kimmelman; Amanda Souza; Kerry A. Pierce

Most patients with pancreatic ductal adenocarcinoma (PDAC) are diagnosed with advanced disease and survive less than 12 months. PDAC has been linked with obesity and glucose intolerance, but whether changes in circulating metabolites are associated with early cancer progression is unknown. To better understand metabolic derangements associated with early disease, we profiled metabolites in prediagnostic plasma from individuals with pancreatic cancer (cases) and matched controls from four prospective cohort studies. We find that elevated plasma levels of branched-chain amino acids (BCAAs) are associated with a greater than twofold increased risk of future pancreatic cancer diagnosis. This elevated risk was independent of known predisposing factors, with the strongest association observed among subjects with samples collected 2 to 5 years before diagnosis, when occult disease is probably present. We show that plasma BCAAs are also elevated in mice with early-stage pancreatic cancers driven by mutant Kras expression but not in mice with Kras-driven tumors in other tissues, and that breakdown of tissue protein accounts for the increase in plasma BCAAs that accompanies early-stage disease. Together, these findings suggest that increased whole-body protein breakdown is an early event in development of PDAC.


Nature Communications | 2013

Reductive glutamine metabolism is a function of the α-ketoglutarate to citrate ratio in cells

Sarah-Maria Fendt; Eric L. Bell; Mark A. Keibler; Benjamin A. Olenchock; Jared R. Mayers; Thomas M. Wasylenko; Natalie I. Vokes; Leonard Guarente; Matthew G. Vander Heiden; Gregory Stephanopoulos

Reductively metabolized glutamine is a major cellular carbon source for fatty acid synthesis during hypoxia or when mitochondrial respiration is impaired. Yet, a mechanistic understanding of what determines reductive metabolism is missing. Here we identify several cellular conditions where the α-ketoglutarate/citrate ratio is changed due to an altered acetyl-CoA to citrate conversion, and demonstrate that reductive glutamine metabolism is initiated in response to perturbations that result in an increase in the α-ketoglutarate/citrate ratio. Thus, targeting reductive glutamine conversion for a therapeutic benefit might require distinct modulations of metabolite concentrations rather than targeting the upstream signalling, which only indirectly affects the process.


Cell Metabolism | 2013

Adipocyte Lipid Chaperone aP2 Is a Secreted Adipokine Regulating Hepatic Glucose Production

Haiming Cao; Motohiro Sekiya; Meric Erikci Ertunc; M. Furkan Burak; Jared R. Mayers; Ariel White; Karen Inouye; Lisa M. Rickey; Baris C. Ercal; Masato Furuhashi; Gürol Tuncman; Gökhan S. Hotamisligil

Proper control of hepatic glucose production is central to whole-body glucose homeostasis, and its disruption plays a major role in diabetes. Here, we demonstrate that although established as an intracellular lipid chaperone, aP2 is in fact actively secreted from adipocytes to control liver glucose metabolism. Secretion of aP2 from adipocytes is regulated by fasting- and lipolysis-related signals, and circulating aP2 levels are markedly elevated in mouse and human obesity. Recombinant aP2 stimulates glucose production and gluconeogenic activity in primary hepatocytes in vitro and in lean mice in vivo. In contrast, neutralization of secreted aP2 reduces glucose production and corrects the diabetic phenotype of obese mice. Hyperinsulinemic-euglycemic and pancreatic clamp studies upon aP2 administration or neutralization demonstrated actions of aP2 in liver. We conclude that aP2 is an adipokine linking adipocytes to hepatic glucose production and that neutralizing secreted aP2 may represent an effective therapeutic strategy against diabetes.


Science | 2016

Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers

Jared R. Mayers; Margaret E. Torrence; Laura V. Danai; Thales Papagiannakopoulos; Shawn M. Davidson; Matthew R. Bauer; Allison N. Lau; Brian W. Ji; Purushottam D. Dixit; Aaron M. Hosios; Alexander Muir; Christopher R. Chin; Elizaveta Freinkman; Tyler Jacks; Brian M. Wolpin; Dennis Vitkup; Matthew G. Vander Heiden

Tumor genetics guides patient selection for many new therapies, and cell culture studies have demonstrated that specific mutations can promote metabolic phenotypes. However, whether tissue context defines cancer dependence on specific metabolic pathways is unknown. Kras activation and Trp53 deletion in the pancreas or the lung result in pancreatic ductal adenocarinoma (PDAC) or non–small cell lung carcinoma (NSCLC), respectively, but despite the same initiating events, these tumors use branched-chain amino acids (BCAAs) differently. NSCLC tumors incorporate free BCAAs into tissue protein and use BCAAs as a nitrogen source, whereas PDAC tumors have decreased BCAA uptake. These differences are reflected in expression levels of BCAA catabolic enzymes in both mice and humans. Loss of Bcat1 and Bcat2, the enzymes responsible for BCAA use, impairs NSCLC tumor formation, but these enzymes are not required for PDAC tumor formation, arguing that tissue of origin is an important determinant of how cancers satisfy their metabolic requirements.


Nature Medicine | 2017

Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors

Shawn M. Davidson; Oliver Jonas; Mark A. Keibler; Han Wei Hou; Alba Luengo; Jared R. Mayers; Jeffrey Wyckoff; Amanda M. Del Rosario; Matthew Whitman; Christopher R. Chin; Kendall Janine Condon; Alex Lammers; Katherine A Kellersberger; Brian K Stall; Gregory Stephanopoulos; Dafna Bar-Sagi; Jongyoon Han; Joshua D. Rabinowitz; Michael J. Cima; Robert Langer; Matthew G. Vander Heiden

Mammalian tissues rely on a variety of nutrients to support their physiological functions. It is known that altered metabolism is involved in the pathogenesis of cancer, but which nutrients support the inappropriate growth of intact malignant tumors is incompletely understood. Amino acids are essential nutrients for many cancer cells that can be obtained through the scavenging and catabolism of extracellular protein via macropinocytosis. In particular, macropinocytosis can be a nutrient source for pancreatic cancer cells, but it is not fully understood how the tumor environment influences metabolic phenotypes and whether macropinocytosis supports the maintenance of amino acid levels within pancreatic tumors. Here we utilize miniaturized plasma exchange to deliver labeled albumin to tissues in live mice, and we demonstrate that breakdown of albumin contributes to the supply of free amino acids in pancreatic tumors. We also deliver albumin directly into tumors using an implantable microdevice, which was adapted and modified from ref. 9. Following implantation, we directly observe protein catabolism and macropinocytosis in situ by pancreatic cancer cells, but not by adjacent, non-cancerous pancreatic tissue. In addition, we find that intratumoral inhibition of macropinocytosis decreases amino acid levels. Taken together, these data suggest that pancreatic cancer cells consume extracellular protein, including albumin, and that this consumption serves as an important source of amino acids for pancreatic cancer cells in vivo.


The FASEB Journal | 2009

Resveratrol treatment in mice does not elicit the bradycardia and hypothermia associated with calorie restriction

Jared R. Mayers; Benjamin William Iliff; Steven J. Swoap

Dietary supplementation with resveratrol may produce calorie restriction‐like effects on metabolic and longevity endpoints in mice. In this study, we sought to determine whether resveratrol treatment elicited other hallmark changes associated with calorie restriction, namely bradycardia and decreased body temperature. We found that during shortterm treatment, wild‐type mice on a calorie‐restricted diet experienced significant decreases in both heart rate and body temperature after only 1 day whereas those receiving resveratrol exhibited no such change after 1 wk. We also used ob/ob mice to study the effects of long‐term treatment because previous studies had indicated the therapeutic value of resveratrol against the linked morbidities of obesity and diabetes. After 12 wk, resveratrol treatment had produced no changes in either heart rate or body temperature. Strikingly, and in contrast to previous findings, we found that resveratrol‐treated mice had significantly reduced endurance in a treadmill test. Quantitative reverse transcriptase‐polymerase chain reaction suggested that a proposed target of resveratrol, Sirt1, was activated in resveratrol‐treated ob/ob mice. Thus, we conclude that the bradycardia and hypothermia associated with calorie restriction occur through mechanisms unaffected by the actions of resveratrol and that further studies are needed to examine the differential effects of resveratrol in a leptin‐deficient background.—Mayers, J. R., Iliff, B. W., Swoap, S. J. Resveratrol treatment in mice does not elicit the bradycardia and hypothermia associated with calorie restriction. FASEB J. 23, 1032–1040 (2009)


Nature Communications | 2017

Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions

Orianne Olivares; Jared R. Mayers; Victoire Gouirand; Margaret E. Torrence; Tristan Gicquel; Laurence Borge; Sophie Lac; Julie Roques; Marie-Noëlle Lavaut; Patrice Berthezene; Marion Rubis; Véronique Secq; Stéphane Garcia; Vincent Moutardier; Dominique Lombardo; Juan L. Iovanna; Richard Tomasini; Fabienne Guillaumond; Matthew G. Vander Heiden; Sophie Vasseur

Tissue architecture contributes to pancreatic ductal adenocarcinoma (PDAC) phenotypes. Cancer cells within PDAC form gland-like structures embedded in a collagen-rich meshwork where nutrients and oxygen are scarce. Altered metabolism is needed for tumour cells to survive in this environment, but the metabolic modifications that allow PDAC cells to endure these conditions are incompletely understood. Here we demonstrate that collagen serves as a proline reservoir for PDAC cells to use as a nutrient source when other fuels are limited. We show PDAC cells are able to take up collagen fragments, which can promote PDAC cell survival under nutrient limited conditions, and that collagen-derived proline contributes to PDAC cell metabolism. Finally, we show that proline oxidase (PRODH1) is required for PDAC cell proliferation in vitro and in vivo. Collectively, our results indicate that PDAC extracellular matrix represents a nutrient reservoir for tumour cells highlighting the metabolic flexibility of this cancer.


Journal of the National Cancer Institute | 2016

Circulating Metabolites and Survival Among Patients With Pancreatic Cancer.

Chen Yuan; Clary B. Clish; Chen Wu; Jared R. Mayers; Peter Kraft; Mary K. Townsend; Mingfeng Zhang; Shelley S. Tworoger; Ying Bao; Zhi Rong Qian; Douglas A. Rubinson; Kimmie Ng; Edward Giovannucci; Shuji Ogino; Meir J. Stampfer; John Michael Gaziano; Jing Ma; Howard D. Sesso; Garnet L. Anderson; Barbara B. Cochrane; JoAnn E. Manson; Margaret E. Torrence; Alec C. Kimmelman; Laufey Amundadottir; Matthew G. Vander Heiden; Charles S. Fuchs; Brian M. Wolpin

BACKGROUND Pancreatic tumors cause changes in whole-body metabolism, but whether prediagnostic circulating metabolites predict survival is unknown. METHODS We measured 82 metabolites by liquid chromatography-mass spectrometry in prediagnostic plasma from 484 pancreatic cancer case patients enrolled in four prospective cohort studies. Association of metabolites with survival was evaluated using Cox proportional hazards models adjusted for age, cohort, race/ethnicity, cancer stage, fasting time, and diagnosis year. After multiple-hypothesis testing correction, a P value of .0006 or less (.05/82) was considered statistically significant. Based on the results, we evaluated 33 tagging single-nucleotide polymorphisms (SNPs) in the ACO1 gene, requiring a P value of less than .002 (.05/33) for statistical significance. All statistical tests were two-sided. RESULTS Two metabolites in the tricarboxylic acid (TCA) cycle--isocitrate and aconitate--were statistically significantly associated with survival. Participants in the highest vs lowest quintile had hazard ratios (HRs) for death of 1.89 (95% confidence interval [CI] = 1.06 to 3.35, Ptrend < .001) for isocitrate and 2.54 (95% CI = 1.42 to 4.54, Ptrend < .001) for aconitate. Isocitrate is interconverted with citrate via the intermediate aconitate in a reaction catalyzed by the enzyme aconitase 1 (ACO1). Therefore, we investigated the citrate to aconitate plus isocitrate ratio and SNPs in the ACO1 gene. The ratio was strongly associated with survival (P trend < .001) as was the SNP rs7874815 in the ACO1 gene (hazard ratio for death per minor allele = 1.37, 95% CI = 1.16 to 1.61, P < .001). Patients had an approximately three-fold hazard for death when possessing one or more minor alleles at rs7874851 and high aconitate or isocitrate. CONCLUSIONS Prediagnostic circulating levels of TCA cycle intermediates and inherited ACO1 genotypes were associated with survival among patients with pancreatic cancer.

Collaboration


Dive into the Jared R. Mayers's collaboration.

Top Co-Authors

Avatar

Matthew G. Vander Heiden

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Margaret E. Torrence

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Shawn M. Davidson

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Allison N. Lau

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gregory Stephanopoulos

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Mark A. Keibler

Massachusetts Institute of Technology

View shared research outputs
Researchain Logo
Decentralizing Knowledge